Open Nav

Landos Biopharma

  • Josep Bassaganya-Riera, Landos Biopharma

Providing updates on Landos' BT-11 clinical development program for ulcerative colitis & Crohn's

  • Date:Wednesday, October 17
  • Time:9:15 AM - 9:30 AM
  • Room:Elizabethan D
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:Landos Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of first-in-class oral therapeutics for patients with autoimmune diseases. Landos’ lead clinical asset, BT-11, is a novel, oral, locally-acting small molecule targeting the Lanthionine Synthetase C-Like 2 (LANCL2) pathway in the gastrointestinal tract for treatment of inflammatory bowel disease (IBD) and is in Phase 1 clinical testing for Crohn’s disease and ulcerative colitis. Landos also has a robust pipeline of compounds for other autoimmune diseases.
  • Company
  • Company HQ City:Blacksburg, VA
  • Company HQ Country:United States
  • Company HQ State:Virginia                        
  • CEO/Top Company Official:Dr. Josep Bassaganya-Riera
  • Year Founded:2017
  • Main Therapeutic Focus:Gastrointestinal
  • Lead Product in Development :BT-11
  • Development Phase of Primary Product:Phase I
  • Previous and Current Investors:Perceptive Advisors
  • Size of Last Investment Round:$10M
  • Total Amount Raised to Date, In All Rounds:$10M